BUSINESS
Kissei to Leverage Its Track Record with EPO to Promote Nesp Biosimilar: President
Kissei Pharmaceutical intends to promote its biosimilar version of Kyowa Kirin’s renal anemia drug Nesp (darbepoetin alfa), which was approved on September 20, by taking advantage of its position in the renal anemia area established through its erythropoietin (EPO) biosimilar…
To read the full story
Related Article
- Japan Clears First Biosimilars for Nesp and Forteo, Second Rituxan, Avastin Follow-Ons Too
September 24, 2019
- Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





